Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (243)	11/7/2002 7:53:21 PM
From: Miljenko Zuanic	Read Replies (1) of 824

OT, (this should be discussed at MLNM tread): WE, <<My notes say trial originally planned for 74 but was expanded to 202 so there should be more than 54 coming.>. I think this was for second PII trial. Originally (first press release for PII) it was planned ~200 pts. Also, as I remember, they announce enrollment completion before deadline for AHS abstract submission, but maybe they didn't have end of treatment data. In addition, they started PIII trial (second line therapy against DEX) before full data on "first relapse PII" were known. So, maybe they have early signal that there is no significant additional benefit with DEX, or that best way to penetrate market is to show superiority over DEX (which I think is reasonable approach). <<...something like "70% population achieves reduction in tumor burden of 30% with V." From 7/16 oncology day CC.>> Is this after adding DEX, or based on V monotherapy? I think that they are holding results for ASH presentation. Words in abstract indicate (gut filing) that there is additional benefit by adding DEX for (at least) pts with stable paraprotein level. They have to differentiate V from CELG thalidomid analogue, if they want to be major player for MM. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next